Cargando…

Pharmacokinetics and Safety of Icotinib Hydrochloride Cream in Patients with Mild to Moderate Chronic Plaque Psoriasis: A Randomized Double-Blind Vehicle-Controlled Phase 1 Study

OBJECTIVE: This phase I study aimed to systematically assess the safety, local tolerability, pharmacokinetics, and preliminary efficacy of topical icotinib hydrochloride cream in patients with mild to moderate plaque psoriasis. MATERIALS AND METHODS: Eligible Chinese adult patients with mild to mode...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Lunfei, Lou, Honggang, Zhou, Jiong, Shen, Ying, Zheng, Min, Ruan, Zourong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2019
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6521334/ https://www.ncbi.nlm.nih.gov/pubmed/31187048 http://dx.doi.org/10.1155/2019/9072683

Ejemplares similares

A double-blind, randomized, placebo- and positive-controlled phase III trial of 1% benvitimod cream in mild-to-moderate plaque psoriasis
por: Cai, Lin, et al.
Publicado: (2020)

First-in-human study to investigate the safety and pharmacokinetics of salvianolic acid A and pharmacokinetic simulation using a physiologically based pharmacokinetic model
por: Chen, Jinliang, et al.
Publicado: (2022)

Tapinarof Cream 1% for Extensive Plaque Psoriasis: A Maximal Use Trial on Safety, Tolerability, and Pharmacokinetics
por: Jett, John E., et al.
Publicado: (2021)

Pharmacokinetics of Roflumilast Cream in Chronic Plaque Psoriasis: Data from Phase I to Phase III Studies
por: Thurston, Archie W., et al.
Publicado: (2022)

Population pharmacokinetics of brodalumab in patients with moderate to severe plaque psoriasis
por: Timmermann, Stine, et al.
Publicado: (2019)

Management of Plaque Psoriasis in Adults: Clinical Utility of Tapinarof Cream
por: Spencer, Riley K, et al.
Publicado: (2023)

Novel topical therapy for mild-to-moderate plaque psoriasis: focus on calcitriol
por: Kowalzick, Lutz
Publicado: (2009)

The Combination of Icotinib Hydrochloride and Fluzoparib Enhances the Radiosensitivity of Biliary Tract Cancer Cells
por: Zhu, Linggang, et al.
Publicado: (2020)

Pharmacokinetics of Risankizumab in Asian Healthy Subjects and Patients With Moderate to Severe Plaque Psoriasis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis
por: Khatri, Amit, et al.
Publicado: (2019)

Development of a particle swarm optimization-backpropagation artificial neural network model and effects of age and gender on pharmacokinetics study of omeprazole enteric-coated tablets in Chinese population
por: Xu, Yichao, et al.
Publicado: (2022)

Asian consensus on assessment and management of mild to moderate plaque psoriasis with topical therapy
por: Imafuku, Shinichi, et al.
Publicado: (2018)

Sensory properties analysis of a calcipotriol and betamethasone dipropionate cream vehicle formulated with an innovative PAD Technology for the treatment of plaque psoriasis on the skin and scalp
por: García, Nuria, et al.
Publicado: (2023)

Lymphocyte subsets in peripheral blood of patients with moderate-to-severe versus mild plaque psoriasis
por: Langewouters, A. M. G., et al.
Publicado: (2007)

Drug–drug interaction study of ciprofol and sodium divalproex: Pharmacokinetics, pharmacodynamics, and safety in healthy Chinese subjects
por: Yang, Dandan, et al.
Publicado: (2023)

Randomized, controlled study of bleselumab (ASKP1240) pharmacokinetics and safety in patients with moderate‐to‐severe plaque psoriasis
por: Anil Kumar, Mysore S., et al.
Publicado: (2018)

Calcipotriol and Betamethasone Dipropionate Cream Based on PAD Technology for the Treatment of Plaque Psoriasis: A Narrative Review
por: Torres, Tiago, et al.
Publicado: (2023)

Efficacy of a Topical Formulation of Sodium Bicarbonate in Mild to Moderate Stable Plaque Psoriasis: a Randomized, Blinded, Intrapatient, Controlled Study
por: Mazzarello, Vittorio, et al.
Publicado: (2019)

Population pharmacokinetic and exposure–efficacy analysis of ixekizumab in paediatric patients with moderate‐to‐severe plaque psoriasis (IXORA‐PEDS)
por: Jackson, Kimberley, et al.
Publicado: (2021)

Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis
por: Gisondi, Paolo, et al.
Publicado: (2016)

Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
por: Blair, Hannah A.
Publicado: (2020)

Non‐invasive clinical and microscopic evaluation of the response to treatment with clobetasol cream vs. calcipotriol/betamethasone dipropionate foam in mild to moderate plaque psoriasis: an investigator‐initiated, phase IV, unicentric, open, randomized clinical trial
por: Yélamos, O., et al.
Publicado: (2020)

Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis
por: Hoy, Sheridan M.
Publicado: (2022)

Characterizing Outcomes and Unmet Needs Among Patients in the United States with Mild-to-Moderate Plaque Psoriasis Using Prescription Topicals
por: Gupta, Shaloo, et al.
Publicado: (2021)

Moderate and severe plaque psoriasis: cost-of-illness study in Italy
por: Colombo, GL, et al.
Publicado: (2008)

The experience of pain and redness in patients with moderate to severe plaque psoriasis
por: Martin, Mona L., et al.
Publicado: (2015)

Potential role of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
por: Ren, Vicky, et al.
Publicado: (2013)

Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
por: Sekhon, Sahil, et al.
Publicado: (2017)

Correction to: Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
por: Blair, Hannah A.
Publicado: (2020)

Humanistic and Economic Impact of Moderate to Severe Plaque Psoriasis in Brazil
por: Lopes, Nilcéia, et al.
Publicado: (2019)

Clinical Utility of Guselkumab in the Treatment of Moderate-to-Severe Plaque Psoriasis
por: Light, Jeremy G, et al.
Publicado: (2021)

Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis
por: Blair, Hannah A.
Publicado: (2021)

Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis in the Russian Federation
por: Odnopozova, Liudmila, et al.
Publicado: (2022)

Therapeutic Inertia in the Management of Moderate-to-Severe Plaque Psoriasis in Adolescents
por: MELIN, Audrey, et al.
Publicado: (2021)

Clinical Utility of Deucravacitinib for the Management of Moderate to Severe Plaque Psoriasis
por: Jin, Joy Q, et al.
Publicado: (2023)

Cost-Effectiveness of Targeted Pharmacotherapy for Moderate to Severe Plaque Psoriasis
por: Hendrix, Nathaniel, et al.
Publicado: (2018)

In silico prediction of bioequivalence of atorvastatin tablets based on GastroPlus™ software
por: Wang, Lu, et al.
Publicado: (2023)

Simultaneous HPLC Determination of Butenafine Hydrochloride and Betamethasone in a Cream Formulation
por: Ankam, R., et al.
Publicado: (2009)

A Randomized Controlled Pilot Study: Combined 595‐nm Pulsed Dye Laser Treatment and Oxymetazoline Hydrochloride Topical Cream Superior to Oxymetazoline Hydrochloride Cream for Erythematotelangiectatic Rosacea
por: Sodha, Pooja, et al.
Publicado: (2021)

Correction to: Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis
por: Hoy, Sheridan M.
Publicado: (2023)

Icotinib hydrochloride enhances chemo- and radiosensitivity by inhibiting EGFR signaling and attenuating RAD51 expression and function in Hela S3 cells
por: Wang, Xuanxuan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_no7sitqhqbh5lgd5btp773hcoo